When and how to cover for fungal infections in patients with severe sepsis and septic shock

Current Infectious Disease Reports

Volumn 13, Issue 5, 2011, Pages 426-432

  Allou, Nicolas ^a   Allyn, Jerome ^a   Montravers, Philippe ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Antifungal therapy; Candidemia; Fungal infections; Invasive candidiasis; Septic shock; Severe sepsis

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; POLYENE; TRIAZOLE; VORICONAZOLE;

ABDOMINAL INFECTION; ANTIFUNGAL RESISTANCE; ARTICLE; BLOODSTREAM INFECTION; CANDIDEMIA; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; EARLY DIAGNOSIS; EARLY INTERVENTION; FUNGEMIA; HEART DISEASE; HUMAN; INFECTION RATE; INFECTION RISK; INTENSIVE CARE UNIT; INVASIVE CANDIDIASIS; LABORATORY DIAGNOSIS; LIVER TOXICITY; MYCOSIS; NEPHROTOXICITY; NEUROLOGIC DISEASE; NONHUMAN; PERITONITIS; PROCESS DEVELOPMENT; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEPTIC SHOCK; THERAPY DELAY; UNSPECIFIED SIDE EFFECT;

EID: 80052574168     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-011-0204-x     Document Type: Article

References (50)

1. MD Zilberberg AF Shorr MH Kollef 2008 Secular trends in candidemia-related hospitalization in the United States, 2000-2005 Infect Control Hosp Epidemiol 29 978 980 18715153 10.1086/591033
2. JL Vincent J Rello J Marshall, et al. 2009 International study of the prevalence and outcomes of infection in intensive care units JAMA 302 2323 9 19952319 10.1001/jama.2009.1754 1:CAS:528:DC%2BD1MXhsFCjsr3L A large epidemiologic description of infection issues in ICU patients
3. H Wisplinghoff T Bischoff SM Tallent, et al. 2004 Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study Clin Infect Dis 39 309 317 15306996 10.1086/421946 (Pubitemid 39050477)
4. S Harbarth J Garbino J Pugin, et al. 2003 Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis Am J Med 115 529 535 14599631 10.1016/j.amjmed.2003.07.005 (Pubitemid 37352798)
5. DI Hsu M Nguyen L Nguyen, et al. 2010 A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients J Antimicrob Chemother 65 1765 70 20554567 10.1093/jac/dkq216 1:CAS:528:DC%2BC3cXptVyrur4%3D The authors provide additional proof of the importance of early antifungal therapy
6. M Morrell VJ Fraser MH Kollef 2005 Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality Antimicrob Agents Chemother 49 3640 3645 16127033 10.1128/AAC.49.9.3640-3645.2005 1:CAS:528: DC%2BD2MXpvFKlt7c%3D (Pubitemid 41233011)
7. MD Zilberberg MH Kollef H Arnold, et al. 2010 Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study BMC Infect Dis 10 150 20525301 10.1186/1471-2334- 10-150
8. GS Martin DM Mannino S Eaton, et al. 2003 The epidemiology of sepsis in the United States from 1979 through 2000 N Engl J Med 348 1546 1554 12700374 10.1056/NEJMoa022139 (Pubitemid 36437931)
9. VY Dombrovskiy AA Martin J Sunderram, et al. 2007 Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003 Crit Care Med 35 1244 1250 17414736 10.1097/01.CCM.0000261890.41311.E9 (Pubitemid 46642649)
10. M Ellis U Hedstrom P Jumaa, et al. 2003 Epidemiology, presentation, management and outcome of candidemia in a tertiary care teaching hospital in the United Arab Emirates, 1995-2001 Med Mycol 41 521 528 14725327 10.1080/13693780310001645337 (Pubitemid 38075566)
11. GP Patel D Simon M Scheetz, et al. 2009 The effect of time to antifungal therapy on mortality in Candidemia associated septic shock Am J Ther 16 508 511 19531934 10.1097/MJT.0b013e3181a1afb7
12. C Viscoli C Girmenia A Marinus, et al. 1999 Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC) Clin Infect Dis 28 1071 1079 10452637 10.1086/514731 1:STN:280:DyaK1MznvFOjtA%3D%3D (Pubitemid 29203541)
13. S Hadley WW Lee R Ruthazer, et al. 2002 Candidemia as a cause of septic shock and multiple organ failure in nonimmunocompromised patients Crit Care Med 30 1808 1814 12163798 10.1097/00003246-200208000-00023 (Pubitemid 34879596)
14. JK Chow Y Golan R Ruthazer, et al. 2008 Risk factors for albicans and non-albicans candidemia in the intensive care unit Crit Care Med 36 1993 1998 18552702 10.1097/CCM.0b013e31816fc4cd
15. O Leroy JP Gangneux P Montravers, et al. 2009 Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006) Crit Care Med 37 1612 1618 19325476 10.1097/CCM.0b013e31819efac0 This is one of the first large-scale, prospective epidemiologic studies specifically focusing on ICU characteristics of patients with severe Candida infection
16. LL Horvath BJ George CK Murray, et al. 2004 Direct comparison of the BACTEC 9240 and BacT/ALERT 3D automated blood culture systems for candida growth detection J Clin Microbiol 42 115 118 14715740 10.1128/JCM.42.1.115-118.2004 (Pubitemid 38082707)
17. MT Montagna G Caggiano E Borghi, et al. 2009 The role of the laboratory in the diagnosis of invasive candidiasis Drugs 69 Suppl 1 59 63 19877736 10.2165/11315630-000000000-00000
18. AC Reboli C Rotstein PG Pappas, et al. 2007 Anidulafungin versus fluconazole for invasive candidiasis N Engl J Med 356 2472 2482 17568028 10.1056/NEJMoa066906 1:CAS:528:DC%2BD2sXms1Sis7w%3D (Pubitemid 46919773)
19. PG Pappas CA Kauffman D Andes, et al. 2009 Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America Clin Infect Dis 48 503 535 19191635 10.1086/596757 1:CAS:528:DC%2BD1MXjslantLY%3D The IDSA guidelines define the recommended management of severe Candida infections
20. D Pittet M Monod PM Suter, et al. 1994 Candida colonization and subsequent infections in critically ill surgical patients Ann Surg 220 751 758 7986142 10.1097/00000658-199412000-00008 1:STN:280:DyaK2M%2FnslCktA%3D%3D (Pubitemid 24376373)
21. C Leon S Ruiz-Santana P Saavedra, et al. 2006 A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization Crit Care Med 34 730 737 16505659 10.1097/01.CCM.0000202208.37364.7D
22. C Leon S Ruiz-Santana P Saavedra, et al. 2009 Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study Crit Care Med 37 1624 1633 19325481 10.1097/CCM. 0b013e31819daa14
23. L Ostrosky-Zeichner C Sable J Sobel, et al. 2007 Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting Eur J Clin Microbiol Infect Dis 26 271 276 17333081 10.1007/s10096-007-0270-z 1:STN:280:DC%2BD2s3gsFGqug%3D%3D (Pubitemid 46572022)
24. L Ostrosky-Zeichner PG Pappas S Shoham, et al. 2011 Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit Mycoses 54 46 51 19627509 10.1111/j.1439-0507.2009.01756.x An interesting approach to improve the relevance of a score for detection of severe Candida infections
25. PD Khot DN Fredricks 2009 PCR-based diagnosis of human fungal infections Expert Rev Anti Infect Ther 7 1201 1221 19968513 10.1586/eri.09.104 1:CAS:528:DC%2BD1MXhsFaqsbbP
26. J Bille 2010 New nonculture-based methods for the diagnosis of invasive candidiasis Curr Opin Crit Care 16 460 464 20736833 10.1097/MCC.0b013e32833e04df
27. BP Guery MC Arendrup G Auzinger, et al. 2009 Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis Intensive Care Med 35 55 62 18972101 10.1007/s00134-008-1338-7 The authors provide an excellent review of this topic from a clinical perspective
28. SF Yeo S Huie AN Sofair, et al. 2006 Measurement of serum D-arabinitol/creatinine ratios for initial diagnosis and for predicting outcome in an unselected, population-based sample of patients with Candida fungemia J Clin Microbiol 44 3894 3899 16957030 10.1128/JCM.01045-06 1:CAS:528: DC%2BD28XhtlSnu7rN (Pubitemid 44737225)
29. P Montravers R Gauzit C Muller, et al. 1996 Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy Clin Infect Dis 23 486 494 8879770 10.1093/clinids/23.3.486 1:STN:280:DyaK2s%2FjsVWisQ%3D%3D (Pubitemid 26304496)
30. P Montravers H Dupont R Gauzit, et al. 2006 Candida as a risk factor for mortality in peritonitis Crit Care Med 34 646 652 16505648 10.1097/01.CCM. 0000201889.39443.D2
31. H Dupont C Paugam-Burtz C Muller-Serieys, et al. 2002 Predictive factors of mortality due to polymicrobial peritonitis with Candida isolation in peritoneal fluid in critically ill patients Arch Surg 137 1341 1346 12470095 10.1001/archsurg.137.12.1341 discussion 1347
32. P Montravers A Chalfine R Gauzit, et al. 2004 Clinical and therapeutic features of nonpostoperative nosocomial intra-abdominal infections Ann Surg 239 409 416 15075660 10.1097/01.sla.0000114214.68169.e9 (Pubitemid 38229072)
33. FC Riche X Dray MJ Laisne, et al. 2009 Factors associated with septic shock and mortality in generalized peritonitis: comparison between community-acquired and postoperative peritonitis Crit Care 13 R99 19552799 10.1186/cc7931
34. H Dupont A Bourichon C Paugam-Burtz, et al. 2003 Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis? Crit Care Med 31 752 757 12626979 10.1097/01.CCM.0000053525.49267.77 (Pubitemid 36379578)
35. P Sandven H Qvist E Skovlund, et al. 2002 Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations Crit Care Med 30 541 547 11990912 10.1097/00003246-200203000-00008 (Pubitemid 34214614)
36. J Mora-Duarte R Betts C Rotstein, et al. 2002 Comparison of caspofungin and amphotericin B for invasive candidiasis N Engl J Med 347 2020 2029 12490683 10.1056/NEJMoa021585 1:CAS:528:DC%2BD38Xps1Ojtbs%3D (Pubitemid 35461658)
37. JH Rex PG Pappas AW Karchmer, et al. 2003 A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects Clin Infect Dis 36 1221 1228 12746765 10.1086/374850 1:CAS:528:DC%2BD3sXltVKjsbw%3D (Pubitemid 36629929)
38. BJ Kullberg JD Sobel M Ruhnke, et al. 2005 Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial Lancet 366 1435 1442 16243088 10.1016/S0140-6736(05)67490-9 1:CAS:528:DC%2BD2MXhtFeiu73J (Pubitemid 41483809)
39. ER Kuse P Chetchotisakd CA da Cunha, et al. 2007 Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial Lancet 369 1519 1527 17482982 10.1016/S0140- 6736(07)60605-9 1:CAS:528:DC%2BD2sXkvFGmt7c%3D (Pubitemid 46670281)
40. BF Dupont O Lortholary L Ostrosky-Zeichner, et al. 2009 Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B Crit Care 13 R159 19804626 10.1186/cc8117 An interesting comparison of ICU and non-ICU patients which suggests that analysis of clinical trials in ICU and in other types of patients is difficult to interpret
41. MA von Mach J Burhenne LS Weilemann 2006 Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy BMC Clin Pharmacol 18 6:6
42. Montravers P, Mira JP, Gangneux JP, et al.: A multicentre study of antifungal strategies and outcome of Candida spp. peritonitis in intensive-care units. Clin Microbiol Infect. 2011;17:1061-7. The first prospective description of a large cohort of patients with Candida peritonitis with relevant data on the therapeutic management of these cases.
43. D Cappelletty K Eiselstein-McKitrick 2007 The echinocandins Pharmacotherapy 27 369 388 17316149 10.1592/phco.27.3.369 1:CAS:528: DC%2BD2sXjsVKks7Y%3D (Pubitemid 46327905)
44. TH Nguyen T Hoppe-Tichy HK Geiss, et al. 2007 Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit J Antimicrob Chemother 60 100 106 17525052 10.1093/jac/dkm125 1:CAS:528:DC%2BD2sXot1ersbY%3D (Pubitemid 47073282)
45. I Spriet P Annaert P Meersseman, et al. 2009 Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation J Antimicrob Chemother 63 767 770 19218271 10.1093/jac/dkp026 1:CAS:528:DC%2BD1MXjt1Gjtrg%3D
46. JH Rex JE Bennett AM Sugar, et al. 1994 A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute N Engl J Med 331 1325 1330 7935701 10.1056/NEJM199411173312001 1:STN:280: DyaK2M%2FitFKisQ%3D%3D (Pubitemid 24347001)
47. PG Pappas CM Rotstein RF Betts, et al. 2007 Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis Clin Infect Dis 45 883 893 17806055 10.1086/520980 1:CAS:528:DC%2BD2sXhtFOntr7I (Pubitemid 47580382)
48. RF Betts M Nucci D Talwar, et al. 2009 A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis Clin Infect Dis 48 1676 1684 19419331 10.1086/598933 1:CAS:528:DC%2BD1MXot12rtrg%3D An interesting approach which demonstrates that dosage is not a major issue with caspofungin
49. RE Lewis 2006 Decision making in antifungal monotherapy versus combination therapy Pharmacotherapy 26 61S 67S 16716124 10.1592/phco.26.6part2. 61S 1:CAS:528:DC%2BD28XmtFansrg%3D (Pubitemid 43807623)
50. M Falcone N Barzaghi G Carosi, et al. 2009 Candida infective endocarditis: report of 15 cases from a prospective multicenter study Medicine (Baltimore) 88 160 168 10.1097/MD.0b013e3181a693f8